Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Published characterization focuses on its receptor-binding profile as a structurally constrained -MSH analog
These include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (common, affecting up to 1 in 10 people) Vomiting (common) Constipation (common) Abdominal pain and discomfort (common) These gastrointestinal effects create the conditions for dehydration , which subsequently causes urine to become concentrated and darker
Given the first-mover commercial advantages documented in biosimilar markets (the first two to three entrants have consistently captured over 90% of biosimilar market share in physician-administered settings), the race-to-market analysis is as commercially important as the patent litigation analysis
What is still being studied Open scientific questions Long-term safety beyond the trial duration, weight regain after discontinuation, comparative effectiveness against Tirzepatide head-to-head, and response variability across populations are all areas where evidence is still maturing
US$ 22.29
US$ 20.62
US$ 25.79
US$ 29.71
US$ 21.14
US$ 23.36
US$ 29.95
US$ 28.76
